Dendreon

...of 21 cents per share and revenues of $580,000. In the latest quarter, the Seattle biotech (NASDAQ: DNDN) reported a one-time $19.4 million charge related to revaluation of warrants. Company officials touted the submission of its...

In this article: Revenue, U.S. Food and Drug Administration, Cancer, DNDN, Nasdaq, and Seattle

...vaccine for prostate-cancer patients. The company is still posting losses -- albeit narrower than last year -- but an FDA nod as early as next year would be a transformative event for the company. Green Mountain Coffee Roasters is the...

In this article: Rackspace, MBIA, Green Mountain Coffee Roasters, Recession, Cancer, FDA, Wal-Mart, and Green Mountain

...treatment Provenge, announced that it had filed an application with the FDA. Provenge extended the lives of late-stage prostate cancer patients by priming their immune systems in one study. Dendreon shares rose 6% to $27 in pre-market trading.

In this article: Human Genome Sciences, Vertex, Cancer, Vertex Pharmaceuticals, U.S. Food and Drug Administration, GlaxoSmithKline, Johnson & Johnson, Telaprevir, and Rash

...the biotech's Provenge prostate cancer drug by May 1, 2010. The Seattle biotech (NASDAQ: DNDN) said the FDA provided written acknowledgment of Dendreon's application for Provenge. When it's approved, "Provenge would represent the first...

In this article: FDA, DNDN, Seattle, Cancer, Nasdaq, Los Angeles, Atlanta, and New Jersey

...cancer. The FDA submission was a bit earlier than expected. The company (NASDAQ: DNDN) earlier this fall said it expected to submit the drug by the middle of November. "With the BLA (Biologics License Application) submission complete,...

In this article: FDA, DNDN, Cancer, Seattle, Nasdaq, Los Angeles, and Atlanta

Dendreon FDA Deadline Set For May 1 Seattle-based Dendreon (NASDAQ: DNDN), the developer of what it hopes will be the first FDA-approved treatment to actively stimulate the immune system against cancer, said today the U.S. regulatory agency...

In this article: FDA, Cancer, Seattle, WordPress, Twitter, and Nasdaq

...cancer," said President and CEO Dr. Mitchell H. Gold said in a statement. The company has previously said it hopes to gain FDA approval and launch the drug in 2010. Shares of Dendreon initially rose as much as $1.61 in early trading Monday...

In this article: Cancer, Food and Drug Administration, and Propecia

...and if it is approved, the stock could see a significant upside. Dendreon is up 507% since last year on positive clinical data, and Cramer thinks Dendreon could go higher. Onyx Pharma's drug Nexavar fights liver and kidney cancer, and...

In this article: Jim Cramer, Kraft, American Express, Bristol-Myers Squibb, ROST, MRK, TJX, and Revenue

...review before it assigns itself a deadline, says Dendreon spokeswoman Katherine Stueland. Dendreon has said it expects to win approval by mid-2010. This deadline matters a lot to Dendreon and prostate cancer patients. Dendreon's stock has...

In this article: FDA, Cancer, Docetaxel, Seattle, Twitter, Nasdaq, and Sanofi-Aventis